Last updated: July 21, 2026
Litigation summary and analysis: JAZZ Pharmaceuticals Ireland Limited v. Lupin Ltd., 2:23-cv-00329
Executive summary
JAZZ PHARMACEUTICALS IRELAND LIMITED sued Lupin Ltd. in U.S. District Court over an FDA Paragraph IV generic challenge tied to a Jazz-branded product. The docket is captioned JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD., case number 2:23-cv-00329. As of the information provided in this prompt, no court filings, patent numbers, asserted claims, settlement status, or substantive decisions are included, so a complete litigation summary cannot be produced without inventing facts.
What is the case posture in JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD., 2:23-cv-00329?
Featured snippet answer: The provided case caption and docket number identify the dispute, but the prompt does not include the complaint details (asserted patents, product at issue, or the stage of proceedings), so the case posture cannot be stated accurately.
What filings typically drive posture in Paragraph IV cases?
- Complaint and notice of alleged infringement (identifies asserted Orange Book patents and claims)
- Answer and defenses (invalidity, non-infringement, procedural defenses)
- Claim construction, summary judgment, or trial schedule orders
- Settlement documentation or stipulations of dismissal (if resolved)
Which patents does Jazz assert against Lupin in 2:23-cv-00329?
Featured snippet answer: Not specified in the prompt.
What details are required to name asserted patents?
A litigation summary must list:
- Orange Book-listed patents asserted by Jazz (patent numbers)
- Each asserted independent claim and dependent claims
- The generic product and the Lupin ANDA number (or equivalent submission)
- The basis for infringement allegations (composition, formulation, method-of-use, or manufacturing)
What Orange Book status drives the Paragraph IV timing for this dispute?
Featured snippet answer: Not provided in the prompt.
Which Orange Book elements are normally summarized?
- Listed patents and their expiration dates
- Exclusivities relevant to the reference listed drug (RLD) (NCE, 5-year, 3-year, orphan, pediatric extensions)
- Listing types (drug substance, drug product, method-of-use)
When does Jazz’s exclusivity end relative to Lupin’s Paragraph IV notice?
Featured snippet answer: Not provided in the prompt.
What timeline fields are typically quantified?
- ANDA submission date
- Paragraph IV notice date (start of 30-month stay)
- 30-month stay expiration
- Earliest theoretical generic launch date absent resolution
- Trigger events for earlier launch (court decision, settlement, or patent lapse)
How strong is Jazz’s patent estate versus Lupin’s generic design-around risk?
Featured snippet answer: Not possible to assess without:
- asserted patents and claim scope
- Lupin’s proposed labeling and formulation/manufacturing details
- any claim construction rulings or invalidity findings
What “strength” metrics are normally reported in litigation analytics?
- PTAB IPR challenges (if any) and outcomes
- Prior art and obviousness posture
- Prior judicial constructions in related cases
- Secondary considerations (if argued)
- Frequency of claim-by-claim infringement wins/losses at motion-to-dismiss or summary judgment
What do the claims and defenses look like in this case?
Featured snippet answer: Not provided in the prompt.
Typical Jazz infringement theories in Orange Book suits
- Composition/formulation patents: differences in amounts, components, or crystallinity/salt forms
- Method-of-use patents: differences in patient population, dosing regimen, or therapeutic indications
- Manufacturing method patents: differences in process controls, crystallization, drying, milling, or scale-up parameters
Typical Lupin defenses
- Non-infringement based on ANDA product characteristics
- Invalidity under 35 USC §§ 101, 102, 103, 112
- Procedural defenses (standing, notice sufficiency, improper venue, timing)
Did the case reach claim construction, summary judgment, or trial?
Featured snippet answer: Not provided in the prompt.
What to report when decisions exist
- Markman/claim construction orders (terms construed, impact on infringement)
- Summary judgment rulings (which patents/claims survive)
- Dismissals for lack of infringement or invalidity
Did the parties settle, and what were the stay or launch terms?
Featured snippet answer: Not provided in the prompt.
Settlement analytics that matter to business decisions
- Dismissal timing and with/without prejudice language
- Agreed launch date (if any)
- Carve-outs for further litigation or non-covered markets/dosage forms
- Exclusivity protection retained by Jazz via licensing or covenant structure
What FDA status applies to the referenced product and Lupin’s ANDA?
Featured snippet answer: Not provided in the prompt.
What regulators’ records usually provide
- RLD identity and indication
- ANDA number, status (pending, approval, tentative approval)
- Approval date and any labeling carve-outs linked to court outcomes
How does this dispute compare with other Jazz v. generic cases?
Featured snippet answer: Not provided in the prompt.
What a useful comparison requires
- Same asserted patents across multiple defendants
- Outcomes in earlier or parallel cases (injunction, invalidation, or settlement)
- PTAB outcomes that affect claim scope across the estate
What generic entry risks exist for Lupin if the litigation ends in Jazz’s favor?
Featured snippet answer: Not possible to compute without:
- asserted patents and expected expiration dates
- any court rulings or stipulated dismissals
Common consequences for generic launch
- Permanent injunction (or exclusion order) for adjudicated patents
- Design-around efforts requiring new ANDA amendments or new patent challenges
- Longer marketing delay even if some patents fall away
What manufacturing and IP barriers could block Lupin’s launch even if patents expire?
Featured snippet answer: Not provided in the prompt.
Typical non-patent blockers
- Data exclusivity still in force
- Patent “evergreening” method-of-use or formulation patents expiring later than the drug substance patent
- FDA CMC hurdles tied to different process or particle properties
Key Takeaways
- The prompt provides only the case caption and docket number (2:23-cv-00329) and does not include the filings needed to produce an accurate litigation summary.
- A complete analysis requires asserted patent numbers, the accused product/ANDA, procedural milestones, and any court rulings or settlement terms. None of these are present in the provided information.
FAQs
What is the meaning of “Paragraph IV” in a Jazz v. Lupin type case?
Paragraph IV refers to an ANDA certification asserting that the Orange Book patents are invalid, unenforceable, or not infringed. It typically triggers a 30-month litigation stay unless the court or settlement changes timing.
Who won in JAZZ PHARMACEUTICALS IRELAND LIMITED v. LUPIN LTD., 2:23-cv-00329?
The prompt does not state the outcome, so it cannot be answered from the provided information.
Does an ANDA settlement always permit a generic launch at an agreed date?
Not always. Some settlements include complex covenants, non-marketing periods, or design-around provisions that can delay or limit launch.
What patents are usually asserted in Orange Book suits for Jazz products?
Common categories include drug substance, drug product (formulation), and method-of-use patents. The exact patents in this case are not provided.
Can PTAB IPR outcomes change the litigation landscape in district court?
Yes. If asserted claims are narrowed or cancelled in PTAB, district court infringement/invalidity analyses can shift, often driving settlement or revised trial posture.
References
- (Not provided in the prompt: court filings, docket text, or patent/Orange Book records for 2:23-cv-00329.)
